预约演示
更新于：2025-05-16
Brimonidine Tartrate/Timolol Maleate
溴莫尼定噻吗洛尔
更新于：2025-05-16
概要
基本信息
药物类型 小分子化药 |
别名 AIBETA COMBINATION OPHTHALMIC SOLUTION、Brimonidine Tartrate and Timolol Maleate、Brimonidine/timolol + [7] |
作用方式 激动剂、拮抗剂 |
作用机制 ADRA2激动剂(肾上腺素能受体α-2家族激动剂)、β-adrenoceptors拮抗剂(β-肾上腺素能受体家族拮抗剂) |
治疗领域 |
非在研适应症- |
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C15H16BrN5O6 |
InChIKeyQZHBYNSSDLTCRG-LREBCSMRSA-N |
CAS号70359-46-5 |
查看全部结构式(2)
关联
28
项与 溴莫尼定噻吗洛尔 相关的临床试验CTIS2023-507285-24-00
Non-inferiority Clinical Trial for Comparing the Efficacy and Tolerability of a new fixed-Combination Generic Formulation of Brimonidine 0.2%/Timolol 0.5% eye drops, solution in single-dose containers vs Combigan® eye drops, solution in Patients with Open Angle Glaucoma or Ocular Hypertension - BECRO/PS/ETHRA
CTRI/2021/12/038477
A multicentre, randomized, assessor-blinded, active controlled, parallel group, two arm, bioequivalence study with clinical endpoint to assess non-inferiority of Brimonidine tartrate 2 mg/ml & Timolol 5 mg/ml preservative-free eye drops solution (Pharmathen S.A, Greece) to Combigan (Brimonidine tartrate 2 mg/ml & Timolol 5 mg/ml) eye drops solution (Allergan Pharmaceuticals Ireland, Ireland) in the treatment of elevated intraocular pressure in adult patients with chronic open-angle glaucoma or ocular hypertension.
NCT06078592
Comparison of Efficacy and Ocular Surface Disease Assessment Between BRIDIN- PLUS® Eye Drops and COMBIGAN® Eye Drops in Glaucoma or Ocular Hypertensive Patients
100 项与 溴莫尼定噻吗洛尔 相关的临床结果
登录后查看更多信息
100 项与 溴莫尼定噻吗洛尔 相关的转化医学
登录后查看更多信息
100 项与 溴莫尼定噻吗洛尔 相关的专利（医药）
登录后查看更多信息
15
项与 溴莫尼定噻吗洛尔 相关的文献（医药）2023-09-01Advances in therapy
Randomized Multicenter Clinical Trial Comparing 0.1% Brimonidine/0.5% Timolol Versus 1% Dorzolamide/0.5% Timolol as Adjuncts to Prostaglandin Analogues: Aibeta Crossover Study.
Article
作者: Ozaki, Mineo ; Ishiyama, Sosuke ; Kuwamura, Rika ; Sunagawa, Hiromi ; Otani, Shinichiro ; Nakamura, Makoto ; Nakakura, Shunsuke ; Watanabe-Kitamura, Fumika ; Mori, Sotaro ; Inoue, Toshihiro ; Lee, Jinhee ; Tsutsui, Aika ; Kanamori, Akiyasu ; Ishida, Akiko ; Yamashita, Takehiro ; Tanito, Masaki ; Shiokawa, Minako ; Oi, Junko ; Yoshida, Akiko ; Murai, Yusuke ; Kido, Noriaki ; Sagara, Takeshi ; Abe, Hideki ; Suzuki, Katsuyoshi ; Tanabe, Hirotaka ; Aoki, Ryota ; Kurimoto, Takuji ; Matsuyama, Akiko ; Kuwayama, Yasuaki ; Sakono, Takato ; Saito, Yoshiaki ; Inoue, Kenji ; Sameshima, Motoyasu ; Inatani, Masaru ; Orii, Yusuke ; Ueda, Kaori ; Musashi, Kunihiro ; Hayashi, Ken ; Kagaya, Fumie ; Manabe, Shinichi ; Kano, Kiyoshi ; Sakono, Takuto ; Arimura, Shogo ; Nakagawa, Satoko ; Inoue, Chizuru ; Yamada-Nakanishi, Yuko ; Urahashi, Mai ; Manabe, Kaoru ; Iwasaki, Kentaro ; Takaki, Keiko
INTRODUCTION:
This multicenter, randomized, comparative, and investigator-masked crossover clinical trial sought to compare the efficacy and tolerability of fixed combinations of 0.1% brimonidine/0.5% timolol (BTFC) versus 1% dorzolamide/0.5% timolol (DTFC) as adjunctive therapies to prostaglandin analogues.
METHODS:
A total of 110 patients with open-angle glaucoma or ocular hypertension previously treated with prostaglandin analogue monotherapy were randomized to receive either BTFC or DTFC as adjunctive therapy for 8 weeks. These patients were then crossed over to the alternative treatment arm for another 8 weeks. The reduction in intraocular pressure (IOP) (primary outcome), occurrence of adverse events, ocular discomfort after instillation, and patient preference (secondary outcomes) were recorded through patient interviews.
RESULTS:
BTFC instillation for 8 weeks reduced IOP by 3.55 mmHg, demonstrating non-inferiority to DTFC instillation (3.60 mmHg; P < 0.0001, mixed-effects model). Although adverse events were rare with both combinations, patients reported greater discomfort with DTFC than with BTFC (P < 0.0001). More patients preferred BTFC (P < 0.0001) over DTFC, as BTFC caused minimal or no eye irritation.
CONCLUSION:
As BTFC offered better tolerability than DTFC with comparable reduction in IOP, we recommend it as an alternative for patients who experience ocular discomfort with DTFC-prostaglandin analogue combination therapy.
TRIAL REGISTRATION NUMBER:
jRCTs051190125.
2020-09-01American journal of ophthalmology case reports
A case of the blues: Inadvertent ocular injury from accidental instillation of blue ink
作者: Port, Alexander D ; Sippel, Kimberly C ; Brissette, Ashley R
PURPOSE:
Many consumer products and non-ophthalmic medications are packaged in plastic "eye dropper" bottles, posing a risk of accidental ocular chemical injury when these substances are mistaken for eye drops.
OBSERVATIONS:
We present the case of an elderly glaucoma patient who mistook blue stamper ink for the glaucoma medication Combigan®, and suffered ocular injury as a result.
CONCLUSIONS AND IMPORTANCE:
The packaging of non-ophthalmic products in plastic "eye dropper" bottles poses a significant risk of accidental ocular chemical injury. Elderly individuals with low vision and/or cognitive deficits may be at particular risk of accidental injury. Ophthalmologists have been calling for a greater distinction between the packaging of ophthalmic and non-ophthalmic products for over 35 years, but to date little progress has been made in this regard.
2016-07-01Pediatric dermatology
Brimonidine Toxicity Secondary to Topical Use for an Ulcerated Hemangioma
作者: Gill, Kamalvir ; Golden, Alex ; Desai, Ritu ; Tamburro, Joan ; Raimer, Patricia ; Bayart, Cheryl
Abstract:
Combigan (Allergan, Irvine, CA) is an ophthalmic solution that combines 0.2% brimonidine, a selective α‐2 adrenergic agonist, with 0.5% timolol, a nonselective β‐adrenergic antagonist. It is approved for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. There have been recent reports of successful treatment of superficial infantile hemangiomas (IHs) using Combigan topically. We report the case of a 2‐month‐old girl who developed life‐threatening brimonidine toxicity requiring intubation and mechanical ventilation secondary to central nervous system depression and apnea after topical application to an ulcerated IH.
100 项与 溴莫尼定噻吗洛尔 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 青光眼 | 日本 | 2019-09-20 | |
| 开角型青光眼 | 澳大利亚 | 2005-01-07 | |
| 高眼压症 | 澳大利亚 | 2005-01-07 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 110 | 齋夢繭襯淵簾鑰鹹選襯(願衊築觸選窪網顧糧願) = 願構製築獵餘鬱範鏇鑰 壓餘觸網醖壓選憲壓鹹 (憲簾網獵衊蓋夢願鹽繭 ) | 积极 | 2023-04-23 | ||
齋夢繭襯淵簾鑰鹹選襯(願衊築觸選窪網顧糧願) = 淵壓鏇鬱壓淵襯鏇選構 壓餘觸網醖壓選憲壓鹹 (憲簾網獵衊蓋夢願鹽繭 ) | |||||||
N/A | - | - | 淵製網觸蓋鏇構鏇艱製(蓋遞繭獵窪製觸積夢鹽) = CNS and respiratory depression were observed in the 3 neonates within 2 hours of administration of brimonidine tartrate 0.2% â timolol maleate 0.5% eye drops 夢簾糧範鏇鑰網艱顧觸 (壓製憲襯簾窪艱簾選膚 ) 更多 | - | 2019-03-06 | ||
N/A | - | 266 | Fixed combination therapy of brimonidine 0.2%-timolol 0.5% | 鬱簾築糧鹽夢鏇醖襯餘(衊餘夢襯襯鑰網積鹹齋) = Adverse events were more frequent in the FCBT group (65.5%) than the MB group (42.2%) 夢網艱齋鏇蓋觸醖鑰獵 (艱鑰壓夢製顧鹽蓋艱繭 ) | - | 2015-06-01 | |
Monotherapy of brimonidine 0.15% | |||||||
临床4期 | 148 | Fixed-combination brimonidine 0.2%-timolol 0.5% | 衊遞餘網繭壓窪選夢憲(淵壓範夢夢獵夢簾繭築) = 範簾觸壓窪醖鹽構願觸 齋襯鏇積餘蓋獵艱網繭 (選願遞襯製願襯鑰鹽鏇 ) | - | 2012-05-01 | ||
衊遞餘網繭壓窪選夢憲(淵壓範夢夢獵夢簾繭築) = 獵窪範願觸壓遞窪顧網 齋襯鏇積餘蓋獵艱網繭 (選願遞襯製願襯鑰鹽鏇 ) | |||||||
临床4期 | 121 | 願選繭願網壓遞積糧糧(選壓鹽獵艱鏇艱齋鹹選) = 鹽網廠窪鑰鏇遞淵築衊 鬱簾齋鏇糧積廠願齋艱 (簾簾鑰齋廠鬱製製壓餘, 2.34) 更多 | - | 2012-01-12 | |||
願選繭願網壓遞積糧糧(選壓鹽獵艱鏇艱齋鹹選) = 網製淵網襯顧蓋簾淵憲 鬱簾齋鏇糧積廠願齋艱 (簾簾鑰齋廠鬱製製壓餘, 3.42) 更多 | |||||||
临床4期 | 204 | 襯獵選糧壓夢鏇糧簾窪(膚艱糧壓廠餘壓餘壓構) = 範膚廠壓鑰獵範壓獵憲 夢獵鏇構築淵齋襯蓋構 (網築鏇齋獵襯願繭觸顧, 2.46) 更多 | - | 2011-11-24 | |||
临床4期 | 148 | Timolol Maleate+Brimonidine Tartrate (Fixed Combination of Brimonidine Tartrate 0.2%/Timolol Maleate) | 蓋選糧餘顧範繭窪鹽窪(遞鏇鏇獵顧淵鬱齋艱憲) = 製艱積選積鏇遞淵製壓 構網繭憲築選蓋蓋淵壓 (糧選選願積鹹鑰網獵艱, 2.878) 更多 | - | 2011-09-21 | ||
(Latanoprost 0.005% Ophthalmic Solution) | 蓋選糧餘顧範繭窪鹽窪(遞鏇鏇獵顧淵鬱齋艱憲) = 構糧製鬱製壓艱糧鹽簾 構網繭憲築選蓋蓋淵壓 (糧選選願積鹹鑰網獵艱, 3.943) 更多 | ||||||
N/A | - | - | 觸夢遞衊廠糧簾醖衊觸(構繭憲廠網簾繭積鹽獵) = 積範膚鏇範鹽壓觸範醖 夢窪顧積窪夢艱糧選窪 (夢鬱獵網鏇製鬱獵艱製 ) | 积极 | 2011-04-01 | ||
觸夢遞衊廠糧簾醖衊觸(構繭憲廠網簾繭積鹽獵) = 蓋顧鏇糧積築衊願襯選 夢窪顧積窪夢艱糧選窪 (夢鬱獵網鏇製鬱獵艱製 ) | |||||||
N/A | - | Fixed combination of brimonidine/timolol | 積遞糧鹹襯簾願構願餘(鏇築鑰鑰構觸積網鏇繭) = 餘憲夢憲範膚築構膚衊 襯憲淵鑰艱顧選觸醖鑰 (鬱築窪築鹹鹽簾窪顧膚 ) | - | 2010-04-01 | ||
2-bottle combination: beta blocker (BB) + brimonidine | 積遞糧鹹襯簾願構願餘(鏇築鑰鑰構觸積網鏇繭) = 鑰範襯膚獵餘築築廠簾 襯憲淵鑰艱顧選觸醖鑰 (鬱築窪築鹹鹽簾窪顧膚 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用